LONDON, June 29 (Reuters) - Sanofi-Aventis's diabetes drug Lantus may increase the risk of cancer, according to new but inconclusive studies from experts around Europe. Shares in the French drugmaker ...
LONDON, July 23 (Reuters) - The European Union's drug watchdog cast further doubt on recent studies suggesting a possible cancer risk with Sanofi-Aventis's widely-used Lantus diabetes drug. The ...
The interchangeable biosimilar insulin glargine is approved for U.S. distribution through a newly established subsidiary, Lanexa Biologics. Tang added, “We are incredibly proud of what this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results